Startups
NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin.
NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory.
NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
*Please note*: We do not respond to messages directly through this account. If you would like to get in touch with us, please visit our website (www.nervgen.com) or email us at [email protected].
NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory.
NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
*Please note*: We do not respond to messages directly through this account. If you would like to get in touch with us, please visit our website (www.nervgen.com) or email us at [email protected].
Overview
Location
Canada, British Columbia, Vancouver
Employees
11-50
Phone
+1 778-731-1711
Founded date
2018
Persons 1
| Date | First Name | Last Name | Title | |||
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 27, 2021 | NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board | Vancouver, Canada. October 27, 2021 - NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage... |
| Oct 19, 2021 | NervGen Pharma : Expanding the Status Quo – Diversifying Mainstream Media | By Codi Darnell October 19, 2021 It's October - the month of pumpkin spice, Canadian Thanksgiving and Halloween. While pumpkin spice is the highlight for me, for the three kids in our house, it's Halloween. And the search for the ... |
| Aug 31, 2021 | NervGen Pharma : Chasing Dreams After Disability – Meet The Stubborn Baker | By Codi Darnell August 31, 2021 How many people can look at their chosen career and say 'I chased my dream'? For someone with a disability, breaking into the working world can be a challenge at the best of times, but chasing a dre... |
| Jul 20, 2021 | The Outdoor Diaries: Andy McKenna, Multiple Sclerosis and Mountain Biking | Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it is... |
| Jul 12, 2021 | NervGen Pharma : Expands Alzheimer's Disease Scientific Advisory Board | Vancouver, Canada. July 12, 2021 - NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous ... |
| May 12, 2021 | NERVGEN PHARMA CORP. NervGen Pharma Announces Closing of Overnight Marketed Equity Offering | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Compa... |
| May 6, 2021 | NERVGEN PHARMA CORP. NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291 | Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments ... |
| May 5, 2021 | NERVGEN PHARMA CORP. NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Compan... |
| May 4, 2021 | NERVGEN PHARMA CORP. NervGen Pharma Corp. Announces Overnight Marketed Equity Offering | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company&q... |
Show more
Reviews 0
FAQ about NervGen Pharma Corp.
When was NervGen Pharma Corp. founded?
NervGen Pharma Corp. was founded in 2018.
What has the press written about NervGen Pharma Corp.?
Parsers VC has collected 13 articles mentioning NervGen Pharma Corp., among them “NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board” (Oct 27, 2021) and “NervGen Pharma : Expanding the Status Quo – Diversifying Mainstream Media” (Oct 19, 2021).
Is NervGen Pharma Corp. still active?
Yes, NervGen Pharma Corp. is active; its latest activity on Parsers VC dates from Jul 15, 2022.